Last updated: September 6, 2026
Plitidepsin remains a commercially limited oncology product with a larger but unproven opportunity in COVID-19 and other viral diseases. The drug is marketed in Australia for relapsed or refractory multiple myeloma, but it lacks FDA and European Union approval. Its near-term value depends on whether PharmaMar can generate a new registration-quality dataset, particularly in oncology or a defined antiviral population. Under a base case, global annual sales remain below $25 million through 2030. A successful new approval could support peak sales of roughly $100 million to $300 million, while failure to advance clinical development would leave the product as a niche regional asset.
What is plitidepsin and how does it work?
Plitidepsin, also known as Aplidin, is a synthetic analogue of a marine-derived cyclodepsipeptide originally isolated from the tunicate Aplidium albicans. PharmaMar developed the compound as an anticancer and antiviral agent.
The principal molecular target is eukaryotic elongation factor 1A2, or eEF1A2. Binding to eEF1A2 can disrupt protein synthesis and induce cancer-cell apoptosis. The same mechanism has been studied in viral disease because viruses depend on host-cell translation machinery for replication. Preclinical studies identified antiviral activity against SARS-CoV-2, including activity against variants, at concentrations below those associated with cytotoxicity in some experimental systems (White et al., 2021).
Plitidepsin is administered intravenously. Its administration burden, narrow therapeutic index, and potential for hepatic, muscular, and hematologic toxicity limit its use outside controlled clinical settings.
What is the current development status of plitidepsin?
The development program has two principal branches: multiple myeloma and antiviral therapy.
| Indication |
Development status |
Key result or regulatory position |
| Relapsed or refractory multiple myeloma |
Commercially available in Australia under national approval |
Approved for a restricted population in combination with dexamethasone |
| Multiple myeloma in the European Union |
Not approved |
EMA issued a negative opinion after review of the marketing application |
| COVID-19, hospitalized or high-risk patients |
Investigational |
Phase 3 development did not establish a broadly accepted registration pathway |
| Other viral infections |
Preclinical or early-stage interest |
No established regulatory approval |
| United States |
Not approved |
No FDA marketing authorization |
Multiple myeloma development
The ADMYRE phase 3 study evaluated plitidepsin with dexamethasone in patients with relapsed or refractory multiple myeloma. The trial reported a statistically significant progression-free survival result, but the absolute treatment effect was limited. Regulatory review concluded that the evidence did not establish a favorable overall benefit-risk profile for European approval.
The Australian approval is therefore the key commercial validation for plitidepsin. It does not create a broad global market because treatment is restricted to heavily pretreated patients and competes with proteasome inhibitors, immunomodulatory agents, anti-CD38 antibodies, bispecific antibodies, and CAR-T therapies.
COVID-19 development
PharmaMar repositioned plitidepsin during the COVID-19 pandemic based on preclinical antiviral activity and early clinical signals. The drug advanced into randomized studies in hospitalized patients.
The development case weakened as treatment patterns changed. Hospitalized COVID-19 populations became more heterogeneous, background antiviral therapy improved, and the clinical value of an intravenous host-directed antiviral became harder to demonstrate. A positive laboratory profile did not translate into a clear commercial or regulatory opportunity.
The COVID-19 program should be treated as a high-risk, unvalidated indication rather than a near-term revenue driver. No broad FDA or EMA approval has resulted from the program.
What is the FDA regulatory status of plitidepsin?
Plitidepsin is not approved by the FDA. It has no U.S. prescription market, no U.S. label, and no established U.S. reimbursement pathway.
A future U.S. application would likely require:
- A clearly defined target population.
- At least one adequately controlled pivotal trial.
- A clinically meaningful endpoint.
- A manageable intravenous dosing and safety profile.
- Manufacturing data supporting commercial-scale production.
- A strategy for drug-drug interactions and use in patients with compromised organ function.
The FDA could review plitidepsin through the conventional New Drug Application pathway. Orphan-drug designation could be relevant for a narrowly defined hematologic indication, but designation would not guarantee approval or market exclusivity.
What is the Orange Book status of plitidepsin?
Plitidepsin has no FDA-approved product and therefore has no U.S. Orange Book listing. There are no U.S. Orange Book patent certifications, no listed U.S. drug-substance patent, and no listed U.S. formulation or method-of-use patent associated with an approved plitidepsin product.
As a result, Paragraph IV litigation is not currently the principal U.S. entry risk. The more material U.S. risks are clinical-development failure, lack of approval, manufacturing complexity, and the absence of a reimbursed commercial channel.
What patents protect plitidepsin?
Plitidepsin protection is likely divided among several patent categories rather than one single global patent right:
- Composition-of-matter and derivative patents.
- Synthetic manufacturing processes.
- Crystalline, salt, or solid-state forms.
- Injectable formulations.
- Combination therapy claims.
- Oncology method-of-use claims.
- Antiviral method-of-use claims.
The earliest composition and compound-related patent rights are unlikely to provide long remaining terms in major jurisdictions because the product was first disclosed and developed more than two decades ago. Later-filed process, formulation, and use patents may have later expiration dates, but their commercial value depends on claim scope and validity.
Patent term should be assessed separately in the United States, Europe, Australia, Japan, and other target markets. Patent-family members can have different filing dates, prosecution outcomes, supplementary protection certificates, pediatric extensions, and terminal disclaimers.
How strong is the plitidepsin patent estate?
The estate is stronger as a manufacturing and formulation barrier than as a broad composition barrier.
| Patent layer |
Likely commercial strength |
Strategic assessment |
| Original molecule |
Low to moderate remaining-term value |
Early priority dates limit remaining life |
| Synthetic process |
Moderate to high |
May complicate low-cost generic or follow-on manufacturing |
| Injectable formulation |
Moderate |
Valuable if claims cover the approved presentation |
| Multiple myeloma use |
Moderate |
Dependent on label language and enforceability |
| COVID-19 use |
Low to moderate |
Commercial value is limited without approval |
| New combinations |
Moderate |
Could support lifecycle management |
| Trade secrets and know-how |
High practical relevance |
Marine-derived and complex-peptide production raises execution barriers |
The drug is a complex peptide rather than a conventional small molecule. Generic substitution could therefore face analytical, manufacturing, and regulatory challenges. Those barriers do not create biologic-level exclusivity, however. Plitidepsin is not a monoclonal antibody, and biosimilar rules do not apply.
When does plitidepsin lose exclusivity?
Plitidepsin’s effective exclusivity differs by country.
Australia provides the only established commercial market. The timing of practical generic entry depends on Australian patent rights, data protection, registration requirements, and the willingness of a competitor to develop an injectable complex peptide.
The United States has no commercial exclusivity because the drug is not approved. The European Union also has no commercial exclusivity from an approved product because the medicine has not received EU authorization.
A later patent covering a formulation, manufacturing process, or approved method may extend commercial protection after the earliest compound patent expires. Such patents do not necessarily block all alternative formulations or processes. Freedom-to-operate analysis must be claim-specific.
Are there Paragraph IV challenges or plitidepsin patent lawsuits?
No material U.S. Paragraph IV dispute is associated with an approved plitidepsin product because plitidepsin has no Orange Book-listed U.S. product.
The main historical regulatory dispute concerned the European marketing application and the subsequent review process, not generic patent litigation. There is no established record of a major U.S. generic challenge comparable to disputes involving high-revenue oral oncology products.
Settlement agreements between PharmaMar and generic manufacturers are not a central feature of the current plitidepsin commercial landscape. The absence of such settlements reflects the lack of a U.S. approved market and the product’s small commercial base.
What is the Australian market position for Aplidin?
Australia is the only material approved market cited for Aplidin. The indication is narrow and directed to patients with relapsed or refractory multiple myeloma after extensive prior treatment.
The addressable population is constrained by:
- Low annual incidence of multiple myeloma relative to common solid tumors.
- Improved survival from competing therapies.
- Use in later treatment lines.
- Intravenous administration.
- Need for specialist oncology infrastructure.
- Competition from newer agents with stronger clinical adoption.
Aplidin’s commercial value in Australia is therefore likely to remain modest unless PharmaMar expands the label or secures reimbursement in additional jurisdictions.
Which companies compete with plitidepsin?
Plitidepsin competes against treatment classes rather than one direct substitute.
| Competitive class |
Representative products |
Competitive effect |
| Proteasome inhibitors |
Bortezomib, carfilzomib, ixazomib |
Established use across multiple lines |
| Immunomodulatory drugs |
Lenalidomide, pomalidomide |
Broad experience and oral administration |
| Anti-CD38 antibodies |
Daratumumab, isatuximab |
Strong adoption in combination regimens |
| BCMA-directed therapies |
Idecabtagene vicleucel, ciltacabtagene autoleucel, teclistamab |
High-value options for advanced disease |
| Bispecific antibodies |
Elranatamab and related agents |
Direct competition in heavily pretreated patients |
| Other investigational agents |
CELMoDs, antibody-drug conjugates, cellular therapies |
Continued pressure on late-line positioning |
Plitidepsin would need a differentiated benefit, such as activity in a genetically or clinically defined refractory population, to regain development momentum in multiple myeloma.
What licensing deals affect plitidepsin?
PharmaMar remains the principal developer and rights holder associated with plitidepsin. The product has not generated a major global licensing structure comparable with large oncology assets licensed to multinational pharmaceutical companies.
Regional commercialization and distribution arrangements may exist, but they do not materially change the strategic picture: PharmaMar controls the development narrative, while commercial reach is limited by the lack of U.S. and EU approval.
A licensing transaction would be more likely if a partner received:
- Rights to a defined antiviral indication.
- A late-stage oncology package.
- Access to validated manufacturing technology.
- A regional commercialization opportunity in markets with regulatory precedent.
Without new efficacy data, plitidepsin is unlikely to command a large upfront payment.
What are the manufacturing and intellectual-property barriers?
Manufacturing is a significant practical barrier. Plitidepsin is a complex cyclic peptide requiring controlled synthesis, purification, characterization, and sterile injectable production. The process must manage impurities, stereochemistry, batch consistency, and stability.
The key barriers include:
- Reproducible active pharmaceutical ingredient production.
- Scale-up from clinical to commercial batches.
- Control of process-related impurities.
- Validated sterile filling.
- Stable supply of specialized starting materials.
- Regulatory comparability for any alternative process.
These barriers can delay generic competition, but they also increase PharmaMar’s cost of goods and limit the number of potential commercial partners.
What is the plitidepsin market projection through 2030?
The following projection is a scenario model rather than reported company guidance. It assumes that current approval remains limited and that no broad new approval is obtained.
| Scenario |
2030 global annual sales |
Key assumption |
| Downside |
Less than $5 million |
Australian sales contract and no successful new indication |
| Base case |
$10 million-$25 million |
Stable Australian niche with limited regional growth |
| Upside |
$100 million-$300 million |
Successful approval in a new oncology or antiviral population |
| High case |
More than $300 million |
Broad regulatory expansion plus meaningful treatment adoption |
Base-case outlook
The base case assigns the highest probability to continued niche commercialization. Revenue would come primarily from Australia and potentially small additional markets. The product would remain exposed to declining late-line oncology demand as newer immune-based and cellular therapies expand.
Upside case
The upside case requires a new clinical program with a clear efficacy signal. The most credible path would be a selected relapsed hematologic population or a defined antiviral setting with an unmet need. A broad COVID-19 opportunity is less attractive than it was during the pandemic because treatment options and vaccination coverage have changed.
A $100 million-plus opportunity would require more than regulatory approval. PharmaMar would need reimbursement, treatment guidelines, reliable manufacturing, and a partner with specialist commercial reach.
Revenue exposure for PharmaMar
Plitidepsin is unlikely to be a primary driver of PharmaMar’s consolidated revenue. The company’s financial exposure is more closely linked to other oncology products, especially Zepzelca, than to Aplidin. This reduces the immediate financial impact of a stalled plitidepsin program but also limits the internal incentive for large-scale investment without a strong probability-adjusted return.
How does plitidepsin compare with other PharmaMar assets?
| Attribute |
Plitidepsin |
Zepzelca |
| Core indication |
Multiple myeloma and investigational antiviral use |
Small-cell lung cancer |
| U.S. approval |
No |
Yes, under accelerated approval |
| EU approval |
No |
Regulatory status varies by jurisdiction |
| Administration |
Intravenous |
Intravenous |
| Commercial scale |
Limited |
Materially larger |
| Main risk |
Lack of global registration and narrow market |
Confirmatory evidence and competitive oncology positioning |
| Patent value |
Process, formulation, and use claims |
Broader commercial relevance tied to an approved product |
Plitidepsin has scientific optionality but limited regulatory traction. Zepzelca has a stronger commercial platform because it has an FDA-approved indication and a defined oncology market.
What generic entry risks exist for plitidepsin?
Generic entry risk is low in the United States because there is no approved product. In Australia, risk is moderate over the longer term.
Potential entry routes include:
- A conventional generic or hybrid application.
- A complex injectable product supported by comparative quality data.
- A follow-on product using an alternative manufacturing process.
- A competing therapy that does not require direct substitution but displaces Aplidin in treatment guidelines.
The key risk to PharmaMar is not an immediate U.S. Paragraph IV launch. It is gradual erosion of a small niche market if competitors develop lower-cost injectable alternatives or if clinicians move to newer multiple myeloma therapies.
Key Takeaways
- Plitidepsin is commercially available in Australia but is not approved by the FDA or the European Commission.
- Its multiple myeloma opportunity is restricted by late-line positioning and intense competition.
- COVID-19 development created scientific interest but has not produced a broad regulatory or commercial market.
- There is no meaningful U.S. Orange Book or Paragraph IV framework for the product today.
- Original compound patents have limited remaining-term value; manufacturing, formulation, and method-of-use rights are more relevant.
- The base-case 2030 sales outlook is approximately $10 million to $25 million globally.
- A new approval could support $100 million to $300 million in peak annual sales, but that outcome requires new pivotal evidence and commercial expansion.
- Plitidepsin is a niche asset with optionality, not a current large-market product.
FAQs
Is plitidepsin approved for COVID-19?
No. Plitidepsin is not approved by the FDA, EMA, or other major regulators for COVID-19.
Is Aplidin available in the United States?
No. Aplidin is not commercially available through an FDA-approved U.S. prescription product.
Is plitidepsin a biologic or a small molecule?
Plitidepsin is a complex cyclic peptide. It is not a monoclonal antibody and is not regulated through the biosimilar pathway used for biologic products.
Can a generic company copy plitidepsin?
A competitor could potentially develop a competing injectable product, but chemical complexity, manufacturing controls, formulation requirements, and jurisdiction-specific patents create meaningful development barriers.
What would most increase the value of plitidepsin?
A successful pivotal trial in a clearly defined population would create the largest value increase. A new FDA or European approval would be more commercially important than incremental expansion of the existing Australian market.
References
-
European Medicines Agency. (2017). Aplidin: EPAR summary for the public and assessment information. EMA.
-
Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
PharmaMar, S.A. (2024). Annual report and financial information. PharmaMar.
-
ClinicalTrials.gov. (n.d.). Study of plitidepsin in patients with relapsed or refractory multiple myeloma: NCT01102426. U.S. National Library of Medicine.
-
ClinicalTrials.gov. (n.d.). Study of plitidepsin in adults with COVID-19: NCT04784559. U.S. National Library of Medicine.
-
White, K. M., Rosales, R., Yildiz, S., Kehrer, T., Miorin, L., Moreno, E., ... García-Sastre, A. (2021). Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. Science, 371(6532), 926-931.
-
Therapeutic Goods Administration. (n.d.). Australian Register of Therapeutic Goods. Australian Government Department of Health and Aged Care.
-
World Intellectual Property Organization. (n.d.). PATENTSCOPE international patent database. WIPO.
